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Abstract Ultrasound detection of sub-clinical athero-
sclerosis (ATS) may help identify individuals at high car-
diovascular risk. Most studies evaluated intima-media
thickness (IMT) at carotid level. We compared the rela-
tionships between main cardiovascular risk factors (CVRF)
and five indicators of ATS (IMT, mean and maximal pla-
que thickness, mean and maximal plaque area) at both
carotid and femoral levels. Ultrasound was performed on
496 participants aged 45–64 years randomly selected from
the general population of the Republic of Seychelles.
73.4 % participants had C1 plaque (IMT thickening
C1.2 mm) at carotid level and 67.5 % at femoral level.
Variance (adjusted R2) contributed by age, sex and CVRF
(smoking, LDL-cholesterol, HDL-cholesterol, blood pres-
sure, diabetes) in predicting any of the ATS markers was
larger at femoral than carotid level. At both carotid and
femoral levels, the association between CVRF and ATS
was stronger based on plaque-based markers than IMT.
Our findings show that the associations between CVRF and
ATS markers were stronger at femoral than carotid level,
and with plaque-based markers rather than IMT. Pending
comparison of these markers using harder cardiovascular
endpoints, our findings suggest that markers based on
plaque morphology assessed at femoral artery level might
be useful cardiovascular risk predictors.
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Introduction
Ultrasound screening for pre-symptomatic peripheral ath-
erosclerosis (ATS) is increasingly recognized as a useful
method for enhancing the detection of high risk subjects
beyond cardiovascular risk factors (CVRF) [1–4]. So far,
the assessment of peripheral ATS mainly relied on the
measurement of the intima-media thickness (IMT) on pre-
determined wall segments of the carotid arteries. Carotid
IMT can be considered both as a surrogate marker of
generalized ATS [5] and an independent predictor of car-
diovascular events and mortality [1–3, 6–9]. However,
several limitations have prevented a broad implementation
of this technique into clinical practice, e.g. the lack of
standardized reference cut-off values [10] and the influence
of factors not related to ATS affecting media thickness
[11, 12]. Moreover, concerns have been raised regarding
the small added contribution of carotid IMT to the esti-
mation of an individual’s risk of cardiovascular events as
compared to CVRF alone [13].
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In order to identify possibly better vascular outcomes,
several authors have focused on alternate markers like the
detection of ATS plaques. The presence and burden of
plaques have been associated with incident stroke or myo-
cardial infarction and cardiovascular mortality [1, 14–25],
but methods for quantifying plaques have largely differed
between studies. Given decreased statistical power asso-
ciated with the use of dichotomized variables (i.e. plaque
vs. no plaque), investigators have focused on continuous
quantitative variables, such as plaque thickness [25] and
plaque area [18, 21, 26, 27]. Furthermore, the sites for the
detection of plaques have also varied. Although carotid
arteries have been examined most often [1, 14, 17–19, 21,
22, 24–27], a few studies have assessed the significance of
ATS markers at the femoral artery level [15, 16, 20, 23].
To our best knowledge, the predictive value of plaque area
has not been evaluated at femoral artery level.
Hence, several ultrasound-based ATS markers have
been used and their comparative predictive values are yet
unclear. Large prospective studies will be needed to com-
pare the predictive significance of these different markers.
Pending such costly and years-long longitudinal studies,
useful information can be suggested by comparing the
associations of CVRF with candidate ATS markers at both
carotid and femoral levels.
In this study, we compared the associations between five
ATS markers (mean IMT, mean plaque thickness, maximal
plaque thickness, mean plaque area and maximal plaque
area) and major conventional CVRF in a population-based
sample of middle-aged adults. Furthermore, we compared
these relationships at both the carotid and femoral artery
levels.
Methods
Study population
This study was conducted in the Republic of Seychelles.
The country is an archipelago of 115 islands located
approximately 1,800 km east of Kenya in the Indian Ocean
(African region). About 99 % of the inhabitants live on the
largest three islands and the majority of the population is of
African descent. During the last 2–3 decades, the country
has experienced fast socio-economic growth, largely driven
by booming tourism and fishing industries, and the gross
national product per capita currently exceeds US $ 8000.
CVD accounts for approximately 38 % of total mortality
and life expectancy is 69 years in men and 76 years in
women [28]. A high prevalence of several major risk fac-
tors was found in 1989 and 2004, e.g. high blood pressure,
overweight, and diabetes [29–31]. Consistent with fairly
high levels of risk factors in the population, a previous
study in 1994 showed a high prevalence of peripheral
atherosclerosis (plaques) in the adult population [32].
The design, methods and overall results of this popula-
tion-based study have been reported elsewhere [30, 33].
Briefly, a random sex- and age-stratified sample of all
inhabitants aged 25–64 was drawn using computerized data
of a national population census carried out in 2002 and
thereafter regularly updated by civil status authorities.
From the initial sample of 1,632 individuals, 69 were dead,
abroad or could not be traced and 80.1 % of the remaining
eligible subjects attended the survey. The study was
approved by the Ministry of Health after technical and
ethical reviews and all participants gave written informed
consent.
Study sample
Participants in this study included all 501 consecutive
participants (225 men and 276 women) aged 45–64 who
attended the study during the first 17 weeks. We restricted
ultrasound to this age range because middle-aged individ-
uals are more likely to present ATS plaques than younger
persons. Restriction to a 17-week period corresponded to
the period during which an experienced ultrasonographer
(PY) was available. We excluded 5 subjects for whom
femoral ultrasound could not be performed in good con-
ditions because of excessively deep location of the artery
([4 cm). The total sample for this study includes 496
subjects (223 men and 273 women).
Cardiovascular risk factors
A team of nurses with previous experience in conducting
surveys administered a structured questionnaire and per-
formed a physical examination. Smoking status was defined
as current smoking of at least 1 cigarette per day. Blood
pressure was defined as the average of the last two of three
measurements taken with a mercury sphygmomanometer at
intervals of at least 2 min after the participants had been
seating for at least 30 min and using a cuff size appropriate
for the arm circumference.
Venous blood was drawn in the morning after an over-
night fast. All samples were centrifuged within 2 h of
blood collection and plasma was immediately frozen to
-20 C. Total blood cholesterol, high density lipoprotein
(HDL)-cholesterol and triglycerides were measured by
standard enzymatic colorimetric tests (CHOD-PAP, HDL-
C plus 2nd generation, GPO-PAP, Roche Diagnostics) on a
Hitachi 917 analyzer (Roche Diagnostics). Low density
lipoprotein (LDL)-cholesterol was calculated using the
Friedwald formula.
Fasting glucose was determined on venous blood with a
point-of-care analyzer (Cholestec LDX, Hayward, USA).
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If the value was C5.6 mmol/l, an additional capillary
measurement -adjusted for plasma values- was carried out
(Ascencia Elite glucometer, Bayer) and the average of the
two readings was considered. If blood glucose was
C5.6–7.0 mmol/l, an oral 75-gram glucose tolerance test
was performed. Diabetes mellitus was defined as fasting
blood glucose C7 mmol/l, a 2-h post-load glucose
C11.1 mmol/l, or current hypoglycemic medication [34].
Ultrasonography
High resolution B-mode ultrasound was performed with a
portable system (LOGIQ Book, general electric health
care, Waukesha, USA) connected to a 6–10 MHz linear
array transducer. The ultrasound system was equipped with
a software of arterial wall analysis with a semi-automated
edge detection system and calibrable electronic caliper
(M’ATH, ICN-Metris, Paris, France). All scans and mea-
surements were performed by the same experienced
investigator (PY), who was blinded to the CVRF status of
the subjects. All measurements were performed directly on
frame.
Four vascular sites were examined in all participants: the
right and left carotid and femoral arteries. Carotid arteries
were examined from the supraclavicular fossa to the sub-
mandibular angle, including the common carotid artery
(CCA), the bulb, and the origin of the internal and external
carotid arteries. Femoral arteries were examined from 4 cm
above the bifurcation spur in their common portion (CFA)
to 4 cm in their superficial branch and at the origin of their
profound branch. According to recent consensus recom-
mendations [35], all scans were acquired at a start depth of
3 cm with a 10 MHz probe frequency, allowing the best
image resolution on screen. These parameters could be
adjusted to a maximum of 4 cm for depth and 8 MHz for
probe frequency depending on individual anatomic
considerations.
IMT protocol
Intima-media thickness, defined as the distance from the
leading edge of the lumen-intima interface to the leading
edge of the media-adventitia interface, was measured on
the far wall of both CCAs and CFAs on a 10 mm segment
located 2 cm upstream from the flow divider. Optimal
longitudinal frames of these segments were frozen in late
diastole before analysis with the M’ATH software. The
recorded IMT value was the mean thickness measured
along the whole segment. In case of plaque occurrence on
the reference site, the mean IMT value was substituted for
the maximal thickness of this plaque. Finally, the mean
values on each side were averaged to obtain a single mean
variable at the carotid and femoral levels and a combined
value for all the four sites.
Plaques and ATS burden protocol
ATS plaques were defined as a focal wall thickening
C1,200 lm protruding into the arterial lumen [36, 37].
Plaques were identified on both the near and the far walls in
all the above described arterial segments by thorough
transversal and longitudinal scanning. After detection,
plaques were scanned in the best longitudinal view per-
pendicularly crossing the most prominent part of the
lesions, and scans frozen in late diastole. The ATS burden
was quantified by measuring two parameters, plaque
thickness and plaque area.
Plaque thickness was considered as the distance between
the plaque-lumen interface and the plaque-adventitia interface
of the thickest plaque visualized on each site. We defined
‘‘mean maximal thickness’’ as the average of the maximal
plaque thickness values measured on both left and right sides
at carotid, femoral and overall levels, respectively. If there was
no plaque in one of the considered sites, plaque thickness was
substituted by the IMT value. We defined ‘‘maximal thick-
ness’’ as the maximal plaque thickness observed on either the
left or right sides at carotid, femoral and overall levels,
respectively. In the absence of plaque, maximal plaque
thickness was replaced by the IMT value.
Plaque area was measured for all visible plaques iden-
tified in any of the four defined artery sites. Surface mea-
surement was based on longitudinal views showing the
largest extent of each identified plaque. The perimeter of
each identified plaque was outlined on frame by means of
an electronic cursor and plaque area was automatically
calculated by the software [18, 26]. Maximal plaque area
refers to the largest total plaque surface found on either left
or right side at the carotid, femoral or overall levels,
respectively. Mean plaque area corresponds to the mean of
the total area of all plaques found on both left and right
arteries at carotid, femoral or overall levels, respectively.
Reproducibility
The intra-observer reproducibility was achieved by a sec-
ond evaluation of 40 vascular sites on 10 randomly selected
participants at a time interval of 26–60 days between the
two examinations. The variability for the presence of pla-
ques showed a 95 % agreement between measurements at
the first and second examinations with a Kappa value of 0.9
(P \ 0.001). For carotid IMT, the coefficient of variation
was 4.8 %, which is similar to previous studies on IMT
reproducibility [38]. For femoral IMT, the coefficient was
9.2 %. For maximal plaque thickness, the coefficient of
variation was 9.5 and 6.8 % at carotid and femoral levels,
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respectively. For maximal plaque area, coefficients were
18.8 and 13.9 % at carotid and femoral levels, respectively.
Statistical analysis
The distribution of the different ATS markers was tabu-
lated by sex and age. We used multivariate linear regres-
sion to analyze the independent association between risk
factors and each of the five ATS markers. In order to
facilitate the comparison of various models with different
ATS markers, we displayed the standardized regression
coefficients, which represent the change in the dependent
variables resulting from a change of one standard deviation
in each of the independent variables. We then calculated
the variance (R squared values) of the multivariate models,
i.e. the proportion of variability in the data set that is
accounted for by the independent variables. We displayed
the R2 contributed by all variables (full models) and by
models adjusted only for age and sex. The difference in
variance between the full model and the model with only
age and sex corresponds to the proportion of variability in
predicting the ATS markers that is contributed by the
modifiable risk factors, independent of age and sex. Pear-
son correlation coefficients were calculated both between
different ATS markers and between same makers at carotid
and femoral levels. Significance was defined for two-sided
P values less than 0.05. Analyses were performed with
Stata 8.2.
Results
Clinical, biochemical and ultrasonographic characteristics
of the participants are shown in Table 1. ATS plaques were
detected in the carotid arteries of 368 participants (73.4 %),
of whom 245 had plaques C1,500 lm (49.4 % of all par-
ticipants). In the femoral arteries, plaques were detected in
335 subjects (67.5 %), of whom 274 had plaques C1,500 lm
(55.2 % of all participants). Figure 1 shows the distribution
of plaques identified in any of the four considered carotid
or femoral locations according to age and sex. Men had
plaques on more artery sites than women. The proportion
of men and women with at least 1 plaque on C1 artery site
increased sharply with age. At carotid artery level, uni/
bilateral plaques were located on the site for IMT mea-
surement in only 18/5 subjects (of a total of 368 individuals
with carotid plaques) but in as many as 102/67 subjects at
femoral artery level (of a total of 335 individuals with
femoral plaques). Hence, IMT was measured indepen-
dently of plaques in most instances at carotid level while
IMT represents the thickness of a plaque in approximately
a quarter of subjects at femoral level. Table 2 shows the
mean and maximal values of the considered ATS markers
by sex and age. Mean and maximal ATS markers were
larger in men than in women and these values increased
significantly with age (e.g. confidence intervals [mean ± 1.96
SE] did not overlap in younger and older age categories for
all markers in either gender). The proportional increase
over age was smaller for IMT (up to 50 % increase) than
for thickness and area (up to 400 %). The relative increase
in size of the ATS markers over age was of a similar order
of magnitude in carotid and femoral arteries.
Age was generally the strongest predictor for all ATS
markers in a model of age and sex adjusted multivariate
analysis between risk factors and ATS markers (Table 3).
All risk factors (LDL-cholesterol, HDL-cholesterol, sys-
tolic blood pressure, smoking, diabetes) were strongly
associated with all ATS markers (IMT, thickness and area)
at femoral level, but only LDL cholesterol and blood
pressure were consistently associated with the ATS markers
at carotid level. For most modifiable risk factors, the
strength of the association (i.e. the magnitude of the
regression coefficient) was higher at femoral than carotid
level. Models based on both the carotid and femoral arteries
did not show stronger associations with CVRF than models
based on the femoral arteries alone. Table 4 shows the
variance (adjusted R2) for predicting each of the four ATS
markers in three different models adjusting for 1)age, sex
and all considered modifiable risk factors (LDL-cholesterol,
HDL-cholesterol, systolic blood pressure, smoking and
diabetes mellitus), 2) age and sex only, and 3) modifiable
risk factors only (i.e. variance explained by the full model
minus variance explained by age and sex only). Several
observations can be done. First, variance contributed by
age, sex and risk factors (full model) was larger at femoral
than carotid level, and the larger variance at femoral level
tended to be contributed by both modifiable risk factors and
age/sex. Second, variance contributed by risk factors and
age/sex tended to be larger for plaque-based markers than
for IMT. Third, variance tended to be larger when models
were based on both carotid and femoral arteries vs. either
carotid or femoral site for markers based on mean estimates
(as opposed to models based on maximal plaque thickness
or area). Fourth, modifiable risk factors tended to account
for more variance than age among men while age tended to
contribute more variance in women, particularly at femoral
level. This may be consistent with lower prevalence of
plaques and more favorable levels of risk factors in middle-
aged women than in men.
Finally, all plaque-based markers were highly correlated
with each other (correlation coefficient 0.73–0.97) at both
carotid and femoral levels in men and women (Table 5),
but much less with IMT. This suggests that IMT and pla-
que-based markers may convey different information.
Conversely, the generally high correlation coefficients
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between plaque-based markers suggest that all the consid-
ered plaque-based markers tend to convey similar information.
Correlation coefficients between IMT and plaque-based
markers tended to be higher at femoral than carotid levels,
consistent with a higher proportion of participants for
whom a plaque was measured at the same location as IMT
at femoral than carotid levels. Interestingly, we found
limited correlation between the same markers measured at
carotid vs. femoral level (correlations coefficients ranged
between 0.22 and 0.40, all P \ 0.001, data not shown on
the Table).
Discussion
In this general population of middle-aged adults, ATS
markers were more strongly associated with CVD risk
factors at femoral than carotid artery level and associations
tended to be stronger with plaque-based markers than with
IMT. This study provides a first head-to-head comparison
of IMT, plaque thickness and plaque area at both carotid
and femoral levels, and this is the first study to examine the
‘‘plaque thickness’’ parameter in the femoral artery.
Our findings suggest that the measurements of ATS
markers at the femoral level could better reflect the expo-
sure to risk factors than measurements at the carotid level.
Only few reports have examined the relationship between
peripheral ATS at both carotid and femoral artery levels
and cardiovascular risk. Although our findings are based on
the proxy measurement of CVRF and not on hard CVD
outcomes like myocardial infarction, stroke or CV death, it
is still interesting to relate them with studies that have
correlated ATS markers with incident CVD outcomes. In a
prospective study including 10,000 subjects, Belcaro et al.
found that the incidence of CVD events was associated
with pre-symptomatic peripheral ATS, and that combining
carotid and femoral findings provided incremental predic-
tion as compared to findings at the sole carotid level, but
with no difference between both vascular fields taken
separately [15]. The apparent discrepancy with our results
(larger association between ATS markers and CVRF at
femoral than carotid levels in our study) can be explained
by different factors. First, Belcaro et al. included only very
low-risk subjects in their study (excluding those with dia-
betes mellitus, total cholesterol [5.2 mmol/l and/or
hypertension) who are less likely to develop significant
plaques at any artery level (normal arteries in 79.9 % of
their participants vs. 10.5 % in our study). Second, markers
of CVD risk factors may differ from markers of CVD
events. However, our results concur with findings by Bel-
caro in the sense that combining carotid with femoral
findings might increase the value of ATS markers. In
another prospective study on high risk subjects with stable
angina pectoris (558 patients, median follow-up 3.0 years),
Table 1 Characteristics of the
participants
Diabetes fasting blood glucose
C7 mmol/l or history of
treatment for diabetes
SD standard deviation
P value for the comparison
between men and women
* P \ 0.05, ** P \ 0.01,
*** P \ 0.001
Men (n = 223) Women (n = 273)
Mean/percent SD Mean/percent SD
Age (years) 54.0 5.8 54.1 6.0
Systolic blood pressure (mmHg) 139.9 20.1 135.7** 20.6
Diastolic blood pressure (mmHg) 90.2 11.9 85.9** 12.1
Total cholesterol (mmol/l) 5.6 1.2 5.9** 1.4
LDL-cholesterol (mmol/l) 3.6 1.2 4.0*** 1.3
HDL-cholesterol (mmol/l) 1.4 0.5 1.4 0.4
Body mass index 26.4 5.1 30.0*** 6.0
Current smoking (%) 30.0 3.6***
Blood pressure C 140/90 mmHg (%) 58.3 45.8**
Blood pressure C 140/90 mmHg or treatment (%) 65.5 63.4
Overweight (BMI C 25 kg/m2) (%) 59.2 81.0***
Obesity (BMI C 30 kg/m2) (%) 19.7 44.3***
Diabetes (%) 17.5 21.2*
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Fig. 1 Proportion of subjects with 0, 1, 2, 3, 4 vascular sites with
plaques according to age and sex (maximum 4 = all right and left
carotid and femoral arteries involved)
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a plaque-based score at either carotid or femoral artery levels
was not significantly associated with cardiovascular mor-
tality or myocardial infarction in multivariate analysis, but
the femoral plaque score significantly predicted revascular-
ization [16]. The rationale underlying possibly different
significance of ATS markers according to different arterial
segments is not clear. It has previously been shown that
different determinants were accountable for ATS found in
different arterial segments in symptomatic and asymptom-
atic subjects [39, 40]. Hypotheses for such differential pat-
terns include hemodynamic stress related to arterial
geometry as well as anatomic, cellular and biochemical
variations across different artery locations [41, 42].
In this study, CVRF tended to be more strongly asso-
ciated with plaque-based markers than with IMT, and this
might indirectly suggest that plaque-based markers could
outperform IMT in predicting CVD risk. The value of IMT
vs. plaque-based markers to predict cardiovascular events
has been examined in a few reports with conflicting results.
Consistent with our findings, two cross-sectional studies
found that plaques were associated with established CVD
better than IMT, respectively with ischemic heart disease
in a representative sample of older adults [20], and with
prevalent CVD in hypertensive individuals [37]. However,
the superiority of plaque-based markers over IMT was not
consistently found in prospective studies. In the Rotterdam
study, which included 3,996 adults with a mean follow-up
of 6.1 years, the incidence of stroke was associated more
strongly with carotid IMT than a score of carotid plaques
[19]. In the same study, carotid IMT and the same carotid
plaque score were equally good predictors of incident
myocardial infarctions [1]. In contrast, a similar carotid
plaque-based score largely outperformed carotid IMT for
the prediction of all-cause and cardiovascular mortality in a
cohort study of 367 elderly men [22]. In these two pro-
spective studies, the plaque score was quantified by sum-
ming the number of segments of the carotid arteries in
which a plaque was found, and patients were then grouped
in arbitrarily-defined categories. This categorical approach
might limit the statistical power of analyses and account for
lower prediction of such plaque-based score as compared
to IMT in these studies.
Table 2 Mean values of different markers of peripheral atherosclerosis by sex and age
Men Women
Carotid Femoral Combined Carotid Femoral Combined
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Mean IMT (lm) 45–49 712 18 953 70 831 78 679 8 678*** 33 678*** 17
50–59 726 13 1172 109 949 112 736 20 829** 68 782** 38
55–59 760 19 1143 89 952 95 799 29 937 47 869 30
60–65 793 16 1415 129 1104 136 880 32 1257 67 1069 46
Mean plaque thickness (lm) 45–49 1035 53 1232 84 1133 52 986 44 810*** 44 898** 33
50–59 1270 79 1555 110 1413 73 1127 46 1197** 89 1162*** 52
55–59 1377 78 1678 117 1527 81 1292 62 1255* 61 1274* 45
60–65 1853 107 1906 131 1879 93 1489*** 72 1637* 83 1563*** 63
Maximal plaque thickness (lm) 45–49 1282 81 1454 101 1759 92 1223 97 1002*** 66 1424*** 71
50–59 1503 97 1885 129 2176 113 1368 93 1482* 99 1741** 81
55–59 1718 102 2062 132 2340 109 1591 125 1567* 82 1956 81
60–65 2218 139 2248 144 2738 140 1747** 144 1974* 94 2205*** 87
Mean plaque area (mm2) 45–49 5.3 0.9 11.3 1.8 8.3 1.2 4.0 0.6 3.1*** 0.7 3.6*** 0.5
50–59 9.9 1.8 21.0 3.2 15.5 2.2 5.3** 0.6 8.2*** 1.5 6.8*** 0.8
55–59 10.6 1.7 21.7 3.2 16.1 2.1 8.3 1.1 8.8** 1.2 8.6* 0.9
60–65 20.5 2.6 28.6 4.3 24.5 2.6 12.7** 1.9 15.5*** 1.6 14.1*** 1.4
Maximum plaque area (mm2) 45–49 13.4 1.7 16.7 2.4 22.3 2.7 13.6 1.3 5.5*** 1.1 14.6*** 1.4
50–59 20.1 2.8 28.8 4.0 36.0 4.9 11.9* 0.8 12.5*** 1.9 18.1*** 1.7
55–59 20.1 2.6 30.0 4.0 35.7 4.3 16.5 1.9 13.5** 1.5 21.4* 2.0
60–65 28.5 3.0 36.6 4.1 45.6 5.0 21.1** 2.8 21.7*** 1.9 29.6*** 2.8
SE standard error
P value for the comparison between men and women
* P \ 0.05, ** P \ 0.01, *** P \ 0.001
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To our knowledge, no population-based study has
compared the relationship between IMT and continuous
plaque-based markers (like thickness or area) with car-
diovascular events or conditions. Nevertheless, carotid
plaque area has already been compared to carotid IMT in
selected populations. Carotid plaque area outperformed
IMT for the prediction of cardiovascular events in 152
patients with established coronary artery disease [21], and
was more accurate than IMT for defining patients without
coronary stenosis on CT angiography in a selected
Table 3 Linear regression of main risk factors on different markers of peripheral atherosclerosis at carotid and femoral artery levels
Carotid Femoral Carotid and femoral
Coefficient P Coefficient P Coefficient P
Mean IMT
Age 0.28 \0.001 0.23 \0.001 0.28 \0.001
Sex 0.06 ns -0.14 0.002 -0.11 0.010
LDL-cholesterol 0.11 0.013 0.14 0.001 0.15 \0.001
HDL-cholesterol -0.10 0.018 -0.14 0.001 -0.15 \0.001
Systolic blood pressure 0.12 0.006 0.10 0.017 0.12 0.003
Smoking 0.00 ns 0.21 \0.001 0.19 \0.001
Diabetes 0.05 ns 0.15 0.001 0.15 \0.001
Mean plaque thickness
Age 0.35 \0.001 0.28 \0.001 0.37 \0.001
Sex -0.10 0.019 -0.17 \0.001 -0.17 \0.001
LDL-cholesterol 0.13 0.001 0.16 \0.001 0.18 \0.001
HDL-cholesterol -0.06 ns -0.11 0.005 -0.10 0.004
Systolic blood pressure 0.15 0.001 0.19 \0.001 0.21 \0.001
Smoking 0.09 0.037 0.24 \0.001 0.21 \0.001
Diabetes 0.03 ns 0.11 0.006 0.09 0.015
Maximal plaque thickness
Age 0.30 \0.001 0.28 \0.001 0.30 \0.001
Sex -0.11 0.016 -0.16 \0.001 -0.20 \0.001
LDL-cholesterol 0.15 0.001 0.15 \0.001 0.18 \0.001
HDL-cholesterol -0.02 ns -0.10 0.008 -0.03 ns
Systolic blood pressure 0.15 0.001 0.18 \0.001 0.21 \0.001
Smoking 0.06 ns 0.23 \0.001 0.18 \0.001
Diabetes 0.01 ns 0.10 0.015 0.08 0.054
Mean plaque area
Age 0.27 \0.001 0.19 \0.001 0.26 \0.001
Sex -0.14 0.002 -0.22 \0.001 -0.22 \0.001
LDL-cholesterol 0.18 \0.001 0.13 0.001 0.18 \0.001
HDL-cholesterol -0.08 0.044 -0.10 0.008 -0.12 0.002
Systolic blood pressure 0.13 0.003 0.17 \0.001 0.18 \0.001
Smoking 0.08 0.056 0.27 \0.001 0.23 \0.001
Diabetes 0.07 ns 0.12 0.005 0.12 0.003
Maximal plaque area
Age 0.20 \0.001 0.19 \0.001 0.19 \0.001
Sex -0.15 0.005 -0.24 \0.001 -0.25 \0.001
LDL-cholesterol 0.19 \0.001 0.14 \0.001 0.17 \0.001
HDL-cholesterol -0.08 0.107 -0.10 0.009 -0.06 0.226
Systolic blood pressure 0.15 0.002 0.16 \0.001 0.18 \0.001
Smoking 0.09 0.073 0.24 \0.001 0.22 \0.001
Diabetes 0.10 0.062 0.09 0.023 0.15 0.002
Coefficient normalized beta regression coefficient
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population of patients with known CAD or with moderate
to high CV risk. [27].
Differences in the relationships between different ATS
markers and conventional CVRF have already been found by
others [43], and can be explained by methodological and
physiological factors. From a physiological perspective, IMT is
influenced by both intima and non-intima related processes.
Examples include hypertensive medial hypertrophy [12] or
adaptive responses of IMT to factors not related to ATS such as
shear stress [11]. By contrast, plaques are more specifically
Table 4 Variance in predicting markers of peripheral atherosclerosis at carotid and femoral artery levels attributable to age and conventional
modifiable risk factors
Carotid arteries Femoral arteries Carotid and femoral arteries
Full model Age and sex Risk factors Full model Age and sex Risk factors Full model Age and sex Risk factors
Mean IMT
Men 11.7 5.9 5.8 20.3 4.5 15.8 21.5 5.8 15.7
Women 18.3 13.4 4.9 24.5 18.2 6.3 31.6 23.7 7.9
All 14.8 10.6 4.2 24.2 12.7 11.5 27.5 15.0 12.5
Mean plaque thickness
Men 23.6 18.7 4.9 26.4 8.5 17.9 36.7 19.0 17.7
Women 18.8 14.2 4.6 34.0 22.8 11.2 40.6 28.3 12.3
All 22.1 17.4 4.7 33.7 19.4 14.3 41.4 27.1 14.3
Maximal plaque thickness
Men 19.5 16.2 3.3 23.6 9.4 14.2 26.9 20.5 6.4
Women 14.2 9.3 4.9 31.7 21.3 10.4 29.6 24.9 4.7
All 17.6 13.6 4.0 31.4 18.8 12.6 32.6 21.5 11.1
Mean plaque area
Men 23.8 13.1 10.7 23.5 6.1 17.4 31.8 12.0 19.8
Women 14.7 10.0 4.7 29.5 16.7 12.8 34.5 20.9 13.6
All 20.4 13.2 7.2 30.1 16.6 13.5 35.9 21.0 14.9
Maximal plaque area
Men 22.8 8.7 14.1 19.8 5.1 14.7 22.8 6.6 16.2
Women 7.0 4.0 3.0 28.9 17.4 11.5 22.4 11.8 10.6
All 16.5 8.0 8.5 28.4 16.7 11.7 27.8 14.6 13.2
Full model includes age, sex, LDL-cholesterol. HDL-cholesterol, systolic blood pressure, smoking, and diabetes
Variance for risk factors is estimated by subtracting variance for full model minus variance for age and sex
Table 5 Correlation coefficients between atherosclerosis markers at carotid and femoral artery levels in men and women
IMT Mean plaque thickness Maximal plaque thickness Mean plaque area
Men Women Men Women Men Women Men Women
Carotid
IMT
Mean plaque thickness 0.41 0.52
Maximal plaque thickness 0.35 0.46 0.95 0.95
Mean plaque area 0.46 0.68 0.89 0.83 0.81 0.76
Maximal plaque area 0.42 0.72 0.83 0.73 0.76 0.71 0.96 0.97
Femoral
MT
Mean plaque thickness 0.76 0.79
Maximal plaque thickness 0.70 0.71 0.96 0.95
Mean plaque area 0.79 0.79 0.89 0.91 0.83 0.85
Maximal plaque area 0.73 0.74 0.86 0.88 0.84 0.89 0.97 0.96
P \ 0.001 for all coefficients
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related to the ATS process. Methodologically, the measurement
of plaque-based markers—as compared to IMT—assesses a
frankly pathological process. From a screening perspective,
IMT and plaque-based markers might act as synergistic
rather than redundant approaches [3]. Like Al-Shali et al.
[43], we found a substantially lower correlation between
IMT and plaque-based ATS markers than between the dif-
ferent plaque-based markers, which suggests that IMT and
plaque-based markers may convey different information. As
IMT and plaque-based markers not only differ in their rela-
tionship with the traditional CVRF but also seem to have
different genetic determinants, it has been suggested to
consider them as completely different entities [44]. Thus, the
use of IMT or plaque-based markers as proxy measurements
of atherosclerosis may lead to different conclusions and
might have a complementary role. For example, while car-
otid IMT seems to better predict stroke than plaque-based
markers [19], the use of both types of markers may further
improve risk prediction [24]. Also, IMT may be the only
marker usable in individuals without plaques, particularly at
an early stage of ATS development [45]. Similarly, our
finding that the correlations between the same ATS markers
at carotid and femoral levels were only fair (correlation
coefficients \0.5) suggest that extending measurements of
any ATS marker to both the carotid and femoral levels—as
opposed to screening in only one artery level- might improve
CVD risk prediction.
Some consistency in the high correlation between all pla-
que-based markers can be expected as all these markers inter-
correlate for morphological reasons: e.g. maximum thickness
is a component of mean thickness and plaque thickness is a
component of plaque area. As mean plaque area is based on all
visualized lesions in the considered artery segments, and not
only on the thickest one, one would expect that this indicator
provides the most comprehensive available measurement of
both ATS and life-long exposure to risk factors. However, our
findings did not demonstrate a clear superiority of the area-
based markers as compared to thickness-based markers,
although area-based markers tended to display the highest
variance explained by modifiable risk factors (carotid score
and scores based on carotid and femoral arteries). Of interest,
no other study has yet examined the relationship between
plaque area at femoral level and outcomes (whether CVRF,
established CV disease or incident CV events). In our study,
plaque area was also the least reproducible of the ATS
markers. This is anticipated in view of increased error in
assessing two dimensions (area) vs. one dimension (plaque
thickness). In the future, three-dimensional assessment of
plaque volume might provide an advantage compared to
markers based on area or one-dimension measurements
especially when ad hoc software allowing automatic or semi-
automatic measurement becomes available [18]. Pending
such technological advances, it is easier and quicker to
measure plaque thickness than plaque area, so that a possible
slight advantage of plaque area in terms of prediction of car-
diovascular risk might not be worth the longer time and greater
expertise needed for measurement of area versus thickness.
Our study has several limitations. Its cross-sectional
design does not allow causal inference in the relationships
between CVRF and ATS markers. The relatively small
sample size did not allow to confirm our findings in sub-
groups of participants at intermediate CVD risk, who are
likely to benefit most of screening with such markers for
better risk stratification [46]. Furthermore, the assessment
of the relationship between ATS markers and CVRF can
only suggest a potential role of these markers to predict
cardiovascular risk and need to be confirmed in prospective
studies using hard cardiovascular outcomes. Also, the
predominantly African descent of this population may limit
the generalization of the results to other ethnicities. On the
other hand, the population-based design and high partici-
pation rate are strengths of our study.
In conclusion, while ultrasound detection of subclinical
peripheral atherosclerosis appears to be a promising tool
for the non-invasive identification of subjects at high risk
for cardiovascular disease, there is still ample debate on
which markers and which artery sites can best predict
cardiovascular outcomes. By providing a head to head
comparison of IMT, plaque thickness and plaque area in
relation to CVRF at both the carotid and femoral artery
levels, this study suggests that plaque-based ATS markers,
on one hand, and femoral location, on the other hand,
might play an important role in the prediction of the car-
diovascular risk and should be examined in addition to
IMT or other markers assessed at the sole carotid level in
future prospective studies with hard CVD outcomes.
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